JP4933617B2 - 新規4−アミノ−3−(3−アゾリル−フェノキシメチル)−チエノ[3,2−c]ピリジン−7−カルボン酸誘導体 - Google Patents
新規4−アミノ−3−(3−アゾリル−フェノキシメチル)−チエノ[3,2−c]ピリジン−7−カルボン酸誘導体 Download PDFInfo
- Publication number
- JP4933617B2 JP4933617B2 JP2009517136A JP2009517136A JP4933617B2 JP 4933617 B2 JP4933617 B2 JP 4933617B2 JP 2009517136 A JP2009517136 A JP 2009517136A JP 2009517136 A JP2009517136 A JP 2009517136A JP 4933617 B2 JP4933617 B2 JP 4933617B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- thieno
- pyridine
- carboxylic acid
- phenoxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- WMSGMYVMPUKTHR-UHFFFAOYSA-N NC1=NC=C(C2=C1C(=CS2)COC2=CC(=CC=C2)C=2NC=CC2)C(=O)O Chemical class NC1=NC=C(C2=C1C(=CS2)COC2=CC(=CC=C2)C=2NC=CC2)C(=O)O WMSGMYVMPUKTHR-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 55
- 125000000217 alkyl group Chemical group 0.000 claims description 68
- 125000003545 alkoxy group Chemical group 0.000 claims description 47
- -1 NR 4 R 5 Chemical group 0.000 claims description 45
- 125000003118 aryl group Chemical group 0.000 claims description 28
- 125000001072 heteroaryl group Chemical group 0.000 claims description 27
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 23
- 150000002431 hydrogen Chemical class 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 9
- 150000002148 esters Chemical class 0.000 claims description 9
- 150000001408 amides Chemical class 0.000 claims description 8
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 6
- 229940100389 Sulfonylurea Drugs 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 6
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- YLERNWRRTGQVFY-UHFFFAOYSA-N ethyl 4-amino-3-[[2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C1=NC(C)=NO1 YLERNWRRTGQVFY-UHFFFAOYSA-N 0.000 claims description 5
- CIOMATXTPLZMLY-UHFFFAOYSA-N ethyl 4-amino-3-[[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C=1)=CC=CC=1C1=NN=C(C)O1 CIOMATXTPLZMLY-UHFFFAOYSA-N 0.000 claims description 5
- 125000003107 substituted aryl group Chemical group 0.000 claims description 5
- JNKZFKTWWBVKCR-UHFFFAOYSA-N 4-amino-3-[[2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylic acid Chemical compound CC1=NOC(C=2C=C(OCC=3C4=C(N)N=CC(=C4SC=3)C(O)=O)C(C)=CC=2)=N1 JNKZFKTWWBVKCR-UHFFFAOYSA-N 0.000 claims description 4
- RPPAGCAGWRONGE-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O1C(C)=NN=C1C1=CC=C(C)C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)=C1 RPPAGCAGWRONGE-UHFFFAOYSA-N 0.000 claims description 4
- APUJFHGXZDPCKB-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[5-[4-(2-hydroxyethyl)-5-methyl-1,2,4-triazol-3-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OCCN1C(C)=NN=C1C1=CC=C(C)C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)=C1 APUJFHGXZDPCKB-UHFFFAOYSA-N 0.000 claims description 4
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- QZHSRGLVAPSLEB-UHFFFAOYSA-N ethyl 4-amino-3-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C1=NN=C(C)O1 QZHSRGLVAPSLEB-UHFFFAOYSA-N 0.000 claims description 4
- OYAQYRYYOMJJSG-UHFFFAOYSA-N ethyl 4-amino-3-[[2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C1=NN=C(C)N1 OYAQYRYYOMJJSG-UHFFFAOYSA-N 0.000 claims description 4
- WMGSZPMUWAUUSF-UHFFFAOYSA-N ethyl 4-amino-3-[[3-(2-methyltetrazol-5-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C=1)=CC=CC=1C=1N=NN(C)N=1 WMGSZPMUWAUUSF-UHFFFAOYSA-N 0.000 claims description 4
- WYZGJCNPDSHGDB-UHFFFAOYSA-N ethyl 4-amino-3-[[5-[4-[(4-methoxyphenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C1=NN=C(C)N1CC1=CC=C(OC)C=C1 WYZGJCNPDSHGDB-UHFFFAOYSA-N 0.000 claims description 4
- XSIZGOSSNSXDSD-UHFFFAOYSA-N ethyl 4-amino-3-[[5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C(O1)=NN=C1C1=CC=C(Cl)C=C1 XSIZGOSSNSXDSD-UHFFFAOYSA-N 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- OABLNJAVZZMDFN-UHFFFAOYSA-N 2-hydroxyethylazanium;2,2,2-trifluoroacetate Chemical compound [NH3+]CCO.[O-]C(=O)C(F)(F)F OABLNJAVZZMDFN-UHFFFAOYSA-N 0.000 claims description 3
- UUAGZVNXUKLGHY-UHFFFAOYSA-N 4-amino-3-[[5-[1-[(4-chlorophenyl)methyl]triazol-4-yl]-2-methylphenoxy]methyl]-n-(2-hydroxyethyl)thieno[3,2-c]pyridine-7-carboxamide Chemical compound C1=C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)C(C)=CC=C1C(N=N1)=CN1CC1=CC=C(Cl)C=C1 UUAGZVNXUKLGHY-UHFFFAOYSA-N 0.000 claims description 3
- BNJJEFMOISXVKG-UHFFFAOYSA-N 4-amino-3-[[5-[1-[(4-chlorophenyl)methyl]triazol-4-yl]-2-methylphenoxy]methyl]-n-(2-hydroxyethyl)thieno[3,2-c]pyridine-7-carboxamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.C1=C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)C(C)=CC=C1C(N=N1)=CN1CC1=CC=C(Cl)C=C1 BNJJEFMOISXVKG-UHFFFAOYSA-N 0.000 claims description 3
- IEIMXXWIKSUKGW-UHFFFAOYSA-N 4-amino-3-[[5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylic acid Chemical compound C1=C(OCC=2C3=C(N)N=CC(=C3SC=2)C(O)=O)C(C)=CC=C1C(O1)=NN=C1C1=CC=C(Cl)C=C1 IEIMXXWIKSUKGW-UHFFFAOYSA-N 0.000 claims description 3
- BPARQIQZMPSRMF-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[2-methyl-5-(1-methyltriazol-4-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide Chemical compound C1=C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)C(C)=CC=C1C1=CN(C)N=N1 BPARQIQZMPSRMF-UHFFFAOYSA-N 0.000 claims description 3
- ZYMGUUANOIJMHA-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.O1C(C)=NN=C1C1=CC=C(C)C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)=C1 ZYMGUUANOIJMHA-UHFFFAOYSA-N 0.000 claims description 3
- VZHGRWKDHGBWER-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[3-(2-methyltetrazol-5-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide Chemical compound CN1N=NC(C=2C=C(OCC=3C4=C(N)N=CC(=C4SC=3)C(=O)NCCO)C=CC=2)=N1 VZHGRWKDHGBWER-UHFFFAOYSA-N 0.000 claims description 3
- ZCGAMKQGLVHYAA-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide Chemical compound O1C(C)=NN=C1C1=CC=CC(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)=C1 ZCGAMKQGLVHYAA-UHFFFAOYSA-N 0.000 claims description 3
- OMNDKPHCEKPLNS-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1N=C(C=2C=C(OCC=3C4=C(N)N=CC(=C4SC=3)C(=O)NCCO)C=CC=2)N=N1 OMNDKPHCEKPLNS-UHFFFAOYSA-N 0.000 claims description 3
- UPKRXMXATBJSBW-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[5-[4-[(4-methoxyphenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide Chemical compound C1=CC(OC)=CC=C1CN1C(C=2C=C(OCC=3C4=C(N)N=CC(=C4SC=3)C(=O)NCCO)C(C)=CC=2)=NN=C1C UPKRXMXATBJSBW-UHFFFAOYSA-N 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- FTAQELCQALUNKY-UHFFFAOYSA-N ethyl 4-amino-3-[[5-[1-[(4-chlorophenyl)methyl]triazol-4-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C(N=N1)=CN1CC1=CC=C(Cl)C=C1 FTAQELCQALUNKY-UHFFFAOYSA-N 0.000 claims description 3
- JPPSMKZKSWLWMT-UHFFFAOYSA-N ethyl 4-amino-3-[[5-[5-[(4-chlorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C(O1)=NN=C1CC1=CC=C(Cl)C=C1 JPPSMKZKSWLWMT-UHFFFAOYSA-N 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 229940124530 sulfonamide Drugs 0.000 claims description 3
- 150000003456 sulfonamides Chemical class 0.000 claims description 3
- RZWVSPYEDMAYCV-UHFFFAOYSA-N 4-amino-3-[[5-[5-[(4-chlorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-2-methylphenoxy]methyl]-n-(2-hydroxyethyl)thieno[3,2-c]pyridine-7-carboxamide Chemical compound C1=C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)C(C)=CC=C1C(O1)=NN=C1CC1=CC=C(Cl)C=C1 RZWVSPYEDMAYCV-UHFFFAOYSA-N 0.000 claims description 2
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 230000003796 beauty Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 175
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 81
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 72
- 239000000203 mixture Substances 0.000 description 72
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 62
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 60
- 235000019439 ethyl acetate Nutrition 0.000 description 59
- 239000000243 solution Substances 0.000 description 57
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 44
- 239000011541 reaction mixture Substances 0.000 description 39
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 38
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 36
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 33
- 238000003556 assay Methods 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 28
- 239000012267 brine Substances 0.000 description 28
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 22
- 238000003818 flash chromatography Methods 0.000 description 22
- 239000007787 solid Substances 0.000 description 21
- 238000001816 cooling Methods 0.000 description 18
- 239000000843 powder Substances 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- 239000008346 aqueous phase Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- LXLXFZVZXDUUSO-UHFFFAOYSA-N ethyl 3-(bromomethyl)-4-chlorothieno[3,2-c]pyridine-7-carboxylate Chemical compound CCOC(=O)C1=CN=C(Cl)C2=C1SC=C2CBr LXLXFZVZXDUUSO-UHFFFAOYSA-N 0.000 description 12
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 11
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 10
- 239000007995 HEPES buffer Substances 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 0 CI1CNC*N*(*)C1 Chemical compound CI1CNC*N*(*)C1 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 7
- 229940124647 MEK inhibitor Drugs 0.000 description 7
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 7
- 235000019341 magnesium sulphate Nutrition 0.000 description 7
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- 102000001788 Proto-Oncogene Proteins c-raf Human genes 0.000 description 6
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- KDCZAKFTHLOVMV-UHFFFAOYSA-N ethyl 3-hydroxy-4-methylbenzoate Chemical compound CCOC(=O)C1=CC=C(C)C(O)=C1 KDCZAKFTHLOVMV-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 230000003595 spectral effect Effects 0.000 description 6
- IDWLGHASUQALQM-UHFFFAOYSA-N 2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenol Chemical compound O1C(C)=NN=C1C1=CC=C(C)C(O)=C1 IDWLGHASUQALQM-UHFFFAOYSA-N 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- UQGBMKKFQGYJAT-UHFFFAOYSA-N ethyl 4-chloro-3-[[5-[4-[(4-methoxyphenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C1=NN=C(C)N1CC1=CC=C(OC)C=C1 UQGBMKKFQGYJAT-UHFFFAOYSA-N 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 description 5
- 108010077182 raf Kinases Proteins 0.000 description 5
- 102000009929 raf Kinases Human genes 0.000 description 5
- IZORRBUQWFSCII-UHFFFAOYSA-N 3-(2h-tetrazol-5-yl)phenol Chemical compound OC1=CC=CC(C=2NN=NN=2)=C1 IZORRBUQWFSCII-UHFFFAOYSA-N 0.000 description 4
- DKWHASKCFWELRN-UHFFFAOYSA-N 3-hydroxy-4-methylbenzohydrazide Chemical compound CC1=CC=C(C(=O)NN)C=C1O DKWHASKCFWELRN-UHFFFAOYSA-N 0.000 description 4
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 description 4
- PYCXRTOAPGILPQ-UHFFFAOYSA-N 4-ethynyl-2-(methoxymethoxy)-1-methylbenzene Chemical compound COCOC1=CC(C#C)=CC=C1C PYCXRTOAPGILPQ-UHFFFAOYSA-N 0.000 description 4
- SCHOBDZHGIOLGY-UHFFFAOYSA-N 5-[3-(methoxymethoxy)-4-methylphenyl]-3-methyl-1,2,4-oxadiazole Chemical compound C1=C(C)C(OCOC)=CC(C=2ON=C(C)N=2)=C1 SCHOBDZHGIOLGY-UHFFFAOYSA-N 0.000 description 4
- JUELCFLCBLHOMO-UHFFFAOYSA-N 5-[5-[(4-chlorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-2-methylphenol Chemical compound C1=C(O)C(C)=CC=C1C(O1)=NN=C1CC1=CC=C(Cl)C=C1 JUELCFLCBLHOMO-UHFFFAOYSA-N 0.000 description 4
- VVVBRLLERZUWBH-UHFFFAOYSA-N 5-iodo-2-methylphenol Chemical compound CC1=CC=C(I)C=C1O VVVBRLLERZUWBH-UHFFFAOYSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- OLKBCHFKTWBETL-UHFFFAOYSA-N ethyl 4-chloro-3-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C1=NN=C(C)O1 OLKBCHFKTWBETL-UHFFFAOYSA-N 0.000 description 4
- CPNCLAFQMNEOBX-UHFFFAOYSA-N ethyl 4-chloro-3-[[3-(2-methyltetrazol-5-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C=1)=CC=CC=1C=1N=NN(C)N=1 CPNCLAFQMNEOBX-UHFFFAOYSA-N 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- CZFNISFYDPIDNM-UHFFFAOYSA-N n,n-dimethylformamide;oxolane Chemical compound CN(C)C=O.C1CCOC1 CZFNISFYDPIDNM-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 102000016914 ras Proteins Human genes 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 3
- XEZNGIUYQVAUSS-UHFFFAOYSA-N 18-crown-6 Chemical compound C1COCCOCCOCCOCCOCCO1 XEZNGIUYQVAUSS-UHFFFAOYSA-N 0.000 description 3
- JHHLSEBUCRXEJB-UHFFFAOYSA-N 2-methyl-5-(1-methyltriazol-4-yl)phenol Chemical compound C1=C(O)C(C)=CC=C1C1=CN(C)N=N1 JHHLSEBUCRXEJB-UHFFFAOYSA-N 0.000 description 3
- FVEBEHDLCCULGR-UHFFFAOYSA-N 2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenol Chemical compound CC1=NOC(C=2C=C(O)C(C)=CC=2)=N1 FVEBEHDLCCULGR-UHFFFAOYSA-N 0.000 description 3
- HNKNITPIISXRIV-UHFFFAOYSA-N 3-(2-methyltetrazol-5-yl)phenol Chemical compound CN1N=NC(C=2C=C(O)C=CC=2)=N1 HNKNITPIISXRIV-UHFFFAOYSA-N 0.000 description 3
- IBPCQSLEMFFILD-UHFFFAOYSA-N 3-(5-methyl-1,3,4-oxadiazol-2-yl)phenol Chemical compound O1C(C)=NN=C1C1=CC=CC(O)=C1 IBPCQSLEMFFILD-UHFFFAOYSA-N 0.000 description 3
- QCFGWABDATZLGK-UHFFFAOYSA-N 3-(methoxymethoxy)-4-methylbenzoic acid Chemical compound COCOC1=CC(C(O)=O)=CC=C1C QCFGWABDATZLGK-UHFFFAOYSA-N 0.000 description 3
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 3
- NCDYUWFXWLXIOH-UHFFFAOYSA-N 3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]phenol Chemical compound C1=CC(OC)=CC=C1CN1N=C(C=2C=C(O)C=CC=2)N=N1 NCDYUWFXWLXIOH-UHFFFAOYSA-N 0.000 description 3
- XVCAOKCDHURPLQ-UHFFFAOYSA-N 5-[1-[(4-chlorophenyl)methyl]triazol-4-yl]-2-methylphenol Chemical compound C1=C(O)C(C)=CC=C1C(N=N1)=CN1CC1=CC=C(Cl)C=C1 XVCAOKCDHURPLQ-UHFFFAOYSA-N 0.000 description 3
- XTUDHTVUUSFLAG-UHFFFAOYSA-N 5-[4-[(4-methoxyphenyl)methyl]-5-methyl-1,2,4-triazol-3-yl]-2-methylphenol Chemical compound C1=CC(OC)=CC=C1CN1C(C=2C=C(O)C(C)=CC=2)=NN=C1C XTUDHTVUUSFLAG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 101000577121 Homo sapiens Monocarboxylate transporter 3 Proteins 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 102100025275 Monocarboxylate transporter 3 Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- 239000012496 blank sample Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- WZLSMJXMNRVNLZ-UHFFFAOYSA-N ethyl 3-(methoxymethoxy)-4-methylbenzoate Chemical compound CCOC(=O)C1=CC=C(C)C(OCOC)=C1 WZLSMJXMNRVNLZ-UHFFFAOYSA-N 0.000 description 3
- GOCJQXUBXNFNJR-UHFFFAOYSA-N ethyl 4-amino-3-[[2-methyl-5-(1-methyltriazol-4-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C(=CC=1)C)=CC=1C1=CN(C)N=N1 GOCJQXUBXNFNJR-UHFFFAOYSA-N 0.000 description 3
- GSDTZYJZPDRNCE-UHFFFAOYSA-N ethyl 4-amino-3-[[3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(N)C=2C=1COC(C=1)=CC=CC=1C(=N1)N=NN1CC1=CC=C(OC)C=C1 GSDTZYJZPDRNCE-UHFFFAOYSA-N 0.000 description 3
- YHHFBDJOCXVJCW-UHFFFAOYSA-N ethyl 4-chloro-3-[[2-methyl-5-(1-methyltriazol-4-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C1=CN(C)N=N1 YHHFBDJOCXVJCW-UHFFFAOYSA-N 0.000 description 3
- ONVOSEUBYBLMIZ-UHFFFAOYSA-N ethyl 4-chloro-3-[[2-methyl-5-(4-methyl-1,2,4-triazol-3-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C1=NN=CN1C ONVOSEUBYBLMIZ-UHFFFAOYSA-N 0.000 description 3
- ODGNJHXZFJBIHR-UHFFFAOYSA-N ethyl 4-chloro-3-[[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C=1)=CC=CC=1C1=NN=C(C)O1 ODGNJHXZFJBIHR-UHFFFAOYSA-N 0.000 description 3
- XBYLBELSQNTPNS-UHFFFAOYSA-N ethyl 4-chloro-3-[[3-[2-[(4-methoxyphenyl)methyl]tetrazol-5-yl]phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C=1)=CC=CC=1C(=N1)N=NN1CC1=CC=C(OC)C=C1 XBYLBELSQNTPNS-UHFFFAOYSA-N 0.000 description 3
- YGXSOGWCEPCGJB-UHFFFAOYSA-N ethyl 4-chloro-3-[[5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C(O1)=NN=C1C1=CC=C(Cl)C=C1 YGXSOGWCEPCGJB-UHFFFAOYSA-N 0.000 description 3
- NZHKNWJQSLJQEC-UHFFFAOYSA-N ethyl 4-chloro-3-[[5-[5-[(4-chlorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C(O1)=NN=C1CC1=CC=C(Cl)C=C1 NZHKNWJQSLJQEC-UHFFFAOYSA-N 0.000 description 3
- XHQGLDONDRVSQF-UHFFFAOYSA-N ethyl 4-methyl-3-(2-trimethylsilylethoxymethoxy)benzoate Chemical compound CCOC(=O)C1=CC=C(C)C(OCOCC[Si](C)(C)C)=C1 XHQGLDONDRVSQF-UHFFFAOYSA-N 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 238000000021 kinase assay Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- WYMBJMBBOONNOK-UHFFFAOYSA-N n'-(4-chlorobenzoyl)-3-hydroxy-4-methylbenzohydrazide Chemical compound C1=C(O)C(C)=CC=C1C(=O)NNC(=O)C1=CC=C(Cl)C=C1 WYMBJMBBOONNOK-UHFFFAOYSA-N 0.000 description 3
- WGUCUVWBJHSPCJ-UHFFFAOYSA-N n'-[2-(4-chlorophenyl)acetyl]-3-hydroxy-4-methylbenzohydrazide Chemical compound C1=C(O)C(C)=CC=C1C(=O)NNC(=O)CC1=CC=C(Cl)C=C1 WGUCUVWBJHSPCJ-UHFFFAOYSA-N 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000008057 potassium phosphate buffer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- NDQXKKFRNOPRDW-UHFFFAOYSA-N 1,1,1-triethoxyethane Chemical compound CCOC(C)(OCC)OCC NDQXKKFRNOPRDW-UHFFFAOYSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- QENGPZGAWFQWCZ-UHFFFAOYSA-N 3-Methylthiophene Chemical compound CC=1C=CSC=1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 description 2
- ZQLCWPXBHUALQC-UHFFFAOYSA-N 3-hydroxy-4-methylbenzoic acid Chemical compound CC1=CC=C(C(O)=O)C=C1O ZQLCWPXBHUALQC-UHFFFAOYSA-N 0.000 description 2
- JYDWPGZFOWZTTN-UHFFFAOYSA-N 4-[3-(methoxymethoxy)-4-methylphenyl]-1-methyltriazole Chemical compound C1=C(C)C(OCOC)=CC(C=2N=NN(C)C=2)=C1 JYDWPGZFOWZTTN-UHFFFAOYSA-N 0.000 description 2
- UMVWDFSFXHRLQE-UHFFFAOYSA-N 4-amino-3-[[5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-methylphenoxy]methyl]-n-(2-hydroxyethyl)thieno[3,2-c]pyridine-7-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.C1=C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)C(C)=CC=C1C(O1)=NN=C1C1=CC=C(Cl)C=C1 UMVWDFSFXHRLQE-UHFFFAOYSA-N 0.000 description 2
- KNCOIRWEUUSHQR-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=NOC(C=2C=C(OCC=3C4=C(N)N=CC(=C4SC=3)C(=O)NCCO)C(C)=CC=2)=N1 KNCOIRWEUUSHQR-UHFFFAOYSA-N 0.000 description 2
- OYYHQSVCTVSSBR-UHFFFAOYSA-N 4-amino-n-(2-hydroxyethyl)-3-[[2-methyl-5-(5-methyl-1h-1,2,4-triazol-3-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxamide Chemical compound N1C(C)=NN=C1C1=CC=C(C)C(OCC=2C3=C(N)N=CC(=C3SC=2)C(=O)NCCO)=C1 OYYHQSVCTVSSBR-UHFFFAOYSA-N 0.000 description 2
- MZLJLRVDRKKRNN-UHFFFAOYSA-N 4-iodo-2-(methoxymethoxy)-1-methylbenzene Chemical compound COCOC1=CC(I)=CC=C1C MZLJLRVDRKKRNN-UHFFFAOYSA-N 0.000 description 2
- CFLMTQRKFSALJY-UHFFFAOYSA-N 5-[5-(4-chlorophenyl)-1,3,4-oxadiazol-2-yl]-2-methylphenol Chemical compound C1=C(O)C(C)=CC=C1C1=NN=C(C=2C=CC(Cl)=CC=2)O1 CFLMTQRKFSALJY-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 108020004459 Small interfering RNA Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000005466 alkylenyl group Chemical group 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 229910000365 copper sulfate Inorganic materials 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 239000002178 crystalline material Substances 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- XSYZCZPCBXYQTE-UHFFFAOYSA-N cyclodecylcyclodecane Chemical compound C1CCCCCCCCC1C1CCCCCCCCC1 XSYZCZPCBXYQTE-UHFFFAOYSA-N 0.000 description 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical compound C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 description 2
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- FJCKECJWZHOQRW-UHFFFAOYSA-N ethyl 4-chloro-3-[[2-methyl-5-(3-methyl-1,2,4-oxadiazol-5-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C1=NC(C)=NO1 FJCKECJWZHOQRW-UHFFFAOYSA-N 0.000 description 2
- XACXDPOHHBVSIG-UHFFFAOYSA-N ethyl 4-chloro-3-[[5-[1-[(4-chlorophenyl)methyl]triazol-4-yl]-2-methylphenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylate Chemical compound C=1SC=2C(C(=O)OCC)=CN=C(Cl)C=2C=1COC(C(=CC=1)C)=CC=1C(N=N1)=CN1CC1=CC=C(Cl)C=C1 XACXDPOHHBVSIG-UHFFFAOYSA-N 0.000 description 2
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 229940043355 kinase inhibitor Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- SUXSAJVJYZCZJO-UHFFFAOYSA-N trimethyl-[2-[[2-methyl-5-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy]methoxy]ethyl]silane Chemical compound O1C(C)=NN=C1C1=CC=C(C)C(OCOCC[Si](C)(C)C)=C1 SUXSAJVJYZCZJO-UHFFFAOYSA-N 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- KQNBRMUBPRGXSL-UHFFFAOYSA-N 1-(bromomethyl)-4-chlorobenzene Chemical compound ClC1=CC=C(CBr)C=C1 KQNBRMUBPRGXSL-UHFFFAOYSA-N 0.000 description 1
- MOHYOXXOKFQHDC-UHFFFAOYSA-N 1-(chloromethyl)-4-methoxybenzene Chemical compound COC1=CC=C(CCl)C=C1 MOHYOXXOKFQHDC-UHFFFAOYSA-N 0.000 description 1
- ZHBBTCYVARHHGR-UHFFFAOYSA-N 1-[(4-chlorophenyl)methyl]-4-[3-(methoxymethoxy)-4-methylphenyl]triazole Chemical compound C1=C(C)C(OCOC)=CC(C=2N=NN(CC=3C=CC(Cl)=CC=3)C=2)=C1 ZHBBTCYVARHHGR-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- 125000006039 1-hexenyl group Chemical group 0.000 description 1
- JWAWEQBUZOGIBZ-UHFFFAOYSA-N 1-methyltriazole Chemical compound CN1C=CN=N1 JWAWEQBUZOGIBZ-UHFFFAOYSA-N 0.000 description 1
- 125000006023 1-pentenyl group Chemical group 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- ABUFEAKDTQPJQZ-UHFFFAOYSA-N 2,2-diethylbutane-1,1,1-triol Chemical compound CCC(CC)(CC)C(O)(O)O ABUFEAKDTQPJQZ-UHFFFAOYSA-N 0.000 description 1
- OOQYMADREBUIPL-UHFFFAOYSA-N 2-(3-ethoxyphenyl)-5-methyl-1,3,4-oxadiazole Chemical compound CCOC1=CC=CC(C=2OC(C)=NN=2)=C1 OOQYMADREBUIPL-UHFFFAOYSA-N 0.000 description 1
- UMQUIRYNOVNYPA-UHFFFAOYSA-N 2-(4-chlorophenyl)acetyl chloride Chemical compound ClC(=O)CC1=CC=C(Cl)C=C1 UMQUIRYNOVNYPA-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- 125000006076 2-ethyl-1-butenyl group Chemical group 0.000 description 1
- 125000006040 2-hexenyl group Chemical group 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 description 1
- 125000006024 2-pentenyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- OACGSLLKFCMXSX-UHFFFAOYSA-N 3-hydroxybenzohydrazide Chemical compound NNC(=O)C1=CC=CC(O)=C1 OACGSLLKFCMXSX-UHFFFAOYSA-N 0.000 description 1
- SGHBRHKBCLLVCI-UHFFFAOYSA-N 3-hydroxybenzonitrile Chemical compound OC1=CC=CC(C#N)=C1 SGHBRHKBCLLVCI-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- QRZGNTQIXXRVEI-UHFFFAOYSA-N 4-chloro-3-[[2-methyl-5-(4-methyl-1,2,4-triazol-3-yl)phenoxy]methyl]thieno[3,2-c]pyridine-7-carboxylic acid Chemical compound ClC1=NC=C(C2=C1C(=CS2)COC1=C(C=CC(=C1)C1=NN=CN1C)C)C(=O)O QRZGNTQIXXRVEI-UHFFFAOYSA-N 0.000 description 1
- RKIDDEGICSMIJA-UHFFFAOYSA-N 4-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1 RKIDDEGICSMIJA-UHFFFAOYSA-N 0.000 description 1
- 125000006042 4-hexenyl group Chemical group 0.000 description 1
- 125000003119 4-methyl-3-pentenyl group Chemical group [H]\C(=C(/C([H])([H])[H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- DBFYESDCPWWCHN-UHFFFAOYSA-N 5-amino-2-methylphenol Chemical compound CC1=CC=C(N)C=C1O DBFYESDCPWWCHN-UHFFFAOYSA-N 0.000 description 1
- 125000006043 5-hexenyl group Chemical group 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 101150019464 ARAF gene Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- YCBRQLRCKGFSAR-UHFFFAOYSA-N CC1=[Ar]N=C(c2ccc(C)cc2)O1 Chemical compound CC1=[Ar]N=C(c2ccc(C)cc2)O1 YCBRQLRCKGFSAR-UHFFFAOYSA-N 0.000 description 1
- XAIBRQHJTCNLTQ-UHFFFAOYSA-N CCCC(C1=CC=CC(C)c2c1[s]cc2COc1c(C)ccc(-c2nnc(C)[o]2)c1)=C Chemical compound CCCC(C1=CC=CC(C)c2c1[s]cc2COc1c(C)ccc(-c2nnc(C)[o]2)c1)=C XAIBRQHJTCNLTQ-UHFFFAOYSA-N 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- 239000005973 Carvone Substances 0.000 description 1
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 101000712530 Homo sapiens RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000019149 MAP kinase activity proteins Human genes 0.000 description 1
- 108040008097 MAP kinase activity proteins Proteins 0.000 description 1
- 206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- SNXACINSQZGXKL-UHFFFAOYSA-N OC(C(F)(F)F)=[U] Chemical compound OC(C(F)(F)F)=[U] SNXACINSQZGXKL-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- DHCLVCXQIBBOPH-UHFFFAOYSA-N beta-glycerol phosphate Natural products OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 1
- GHRQXJHBXKYCLZ-UHFFFAOYSA-L beta-glycerolphosphate Chemical compound [Na+].[Na+].CC(CO)OOP([O-])([O-])=O GHRQXJHBXKYCLZ-UHFFFAOYSA-L 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000005980 hexynyl group Chemical group 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 102000057592 human Raf1 Human genes 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- PKAUVIXBZJUYRV-UHFFFAOYSA-N methane;hydroiodide Chemical compound C.I PKAUVIXBZJUYRV-UHFFFAOYSA-N 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- HRDXJKGNWSUIBT-UHFFFAOYSA-N methoxybenzene Chemical group [CH2]OC1=CC=CC=C1 HRDXJKGNWSUIBT-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- AEXITZJSLGALNH-UHFFFAOYSA-N n'-hydroxyethanimidamide Chemical compound CC(N)=NO AEXITZJSLGALNH-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003413 spiro compounds Chemical class 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- NFBJYOHDNFMBHR-UHFFFAOYSA-N thieno[3,2-c]pyridine-7-carboxylic acid Chemical class OC(=O)C1=CN=CC2=C1SC=C2 NFBJYOHDNFMBHR-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- CWMFRHBXRUITQE-UHFFFAOYSA-N trimethylsilylacetylene Chemical compound C[Si](C)(C)C#C CWMFRHBXRUITQE-UHFFFAOYSA-N 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- PXXNTAGJWPJAGM-UHFFFAOYSA-N vertaline Natural products C1C2C=3C=C(OC)C(OC)=CC=3OC(C=C3)=CC=C3CCC(=O)OC1CC1N2CCCC1 PXXNTAGJWPJAGM-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Description
R1は、水素、低級アルキル、低級アルケニル、低級アルキニル、低級アルコキシ、シアノ、NR4R5、トリフルオロメチル及びNO2からなる群より選択され;
R2は例えば、水素、低級アルキル、置換低級アルキル、アリール又はヘテロアリール置換低級アルキル、低級アルケニル、低級アルキニル、低級アルコキシ、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シアノ、ハロゲン、メチルスルホニル、スルホンアミド、トリフルオロメチル、スルホニル尿素、アミド、エステル、カルバメート及び尿素からなる群より選択される1又は2以上の基であり;
R3は、水素、ヒドロキシ、低級アルキル、置換低級アルキル、低級アルコキシ及びNR4R5からなる群より選択され;
環Bは、アリール及びヘテロアリールからなる群より選択され;
環Aは、更に置換されていてもよい
R4及びR5は、水素、低級アルキル、又はヒドロキシ若しくは低級アルコキシで置換された低級アルキルから選択され、
XはO又はNHである)、
及び、医薬的に許容し得るその塩に関する。
R1は、水素、低級アルキル、低級アルケニル、低級アルキニル、低級アルコキシ、シアノ、NR4R5、トリフルオロメチル及びNO2からなる群より選択され;
R2は、水素、低級アルキル、置換低級アルキル、アリール又はヘテロアリール置換低級アルキル、低級アルケニル、低級アルキニル、低級アルコキシ、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シアノ、ハロゲン、メチルスルホニル、スルホンアミド、トリフルオロメチル、スルホニル尿素、アミド、エステル、カルバモイル、カルバメート及び尿素からなる群より選択され;
R3は、水素、低級アルキル、置換低級アルキル、低級アルコキシ及びNR4R5からなる群より選択され;
環Bは、アリール及びヘテロアリールからなる群より選択され;
環Aは、更に置換されていてもよい
R4及びR5は、水素、低級アルキル、又はヒドロキシ若しくは低級アルコキシで置換された低級アルキルから選択され、
XはO又はNHである化合物、並びに、医薬的に許容し得るその塩も包含される。
水素、
低級アルキル、
ヒドロキシ置換低級アルキル、
アリール又はヘテロアリールで置換された低級アルキル(ここでアリール又はヘテロアリールは、ハロゲン又は低級アルキルで置換されていてもよい)、
低級アルケニル、
低級アルキニル、
低級アルコキシ、
アリール、
アリール−低級アルキレニル(ここでアリール基は、低級アルコキシ又はハロゲンで置換されてなる)、
ヘテロアリール、
ヘテロアリール−低級アルキレニル(ここでヘテロアリール基は、低級アルキル、又は、ヒドロキシ置換低級アルキルで置換されてなる)
シアノ、
ハロゲン、
メチルスルホニル、
スルホンアミド、
トリフルオロメチル、
スルホニル尿素、
アミド、
エステル、
カルバメート、及び、
尿素からなる群より選択される、1又は2以上の基である。
R1が、5−置換1−ヒドロキシ環B(ここで環Bはフェニルである)のC2における水素又は低級アルキルであるか、又は、
R1が、5−置換3−ヒドロキシ環B(ここで環Bはピリジンである)のC2における水素又は低級アルキルである化合物が挙げられる。
4−クロロ−3−[3−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル;
4−アミノ−3−[3−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル;
4−アミノ−3−[3−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−クロロ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩、
4−アミノ−3−{5−[4−(2−ヒドロキシ−エチル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩、
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド トルエン−4−スルホン酸塩、
4−クロロ−3−[2−メチル−5−(1−メチル−1H−[1,2,3]トリアゾール−4−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(1−メチル−1H−[1,2,3]トリアゾール−4−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(1−メチル−1H−[1,2,3]トリアゾール−4−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−クロロ−3−{3−[2−(4−メトキシ−ベンジル)−2H−テトラゾール−5−イル]−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{3−[2−(4−メトキシ−ベンジル)−2H−テトラゾール−5−イル]−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{3−[2−(4−メトキシ−ベンジル)−2H−テトラゾール−5−イル]−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−クロロ−3−[3−(2−メチル−2H−テトラゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[3−(2−メチル−2H−テトラゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[3−(2−メチル−2H−テトラゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−クロロ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド トルエン−4−スルホン酸塩、
4−クロロ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−クロロ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸、
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩、
4−クロロ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸、
4−アミノ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ−[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩、
4−クロロ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−クロロ−3−[2−メチル−5−(メチル−4H−[1,2,4]トリアゾール−3−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(5−メチル−4H−[1,2,4]トリアゾール−3−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、及び、
4−アミノ−3−[2−メチル−5−(5−メチル−4H−[1,2,4]トリアゾール−3−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドが挙げられる。
HRMS(ES+) m/z Calcd for C20H18N4O4S + H [(M+H)+]:411.1122。Found: 411.1121。
HRMS(ES+) m/z Calcd for C20H19N5O4S + H [(M+H)+]:426.1231。Found: 426.1227。
HRMS(ES+) m/z Calcd for C21H20N4O4S + H [(M+H)+]:425.1278。Found: 425.1274。
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩
HRMS(ES+) m/z Calcd for C21H21N5O4S + H [(M+H)+]:440.1387。Found: 440.1384。
4−アミノ−3−{5−[4−(2−ヒドロキシ−エチル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩
HRMS(ES+) m/z Calcd for C23H26N6O4S + H [(M+H)+]:483.1809。Found: 483.1808。
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド トルエン−4−スルホン酸塩
HRMS(ES+) m/z Calcd for C21H21N5O4S + H [(M+H)+]:440.1387。Found: 440.1384。
HRMS(ES+) m/z Calcd for C21H21N5O3S + H [(M+H)+]:424.1438。Found: 424.1436。
4−アミノ−3−[2−メチル−5−(1−メチル−1H−[1,2,3]トリアゾール−4−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド
HRMS(ES+) m/z Calcd for C21H22N6O3S + H [(M+H)+]:439.1547。Found: 439.1545。
HRMS(ES+) m/z Calcd for C26H24N6O4S + H [(M+H)+]: 517.1653。Found: 517.1653。
HRMS(ES+) m/z Calcd for C26H25N7O4S + H [(M+H)+]:532.1762。Found:532.1762。
HRMS(ES+) m/z Calcd for C19H18N6O3S + H [(M+H)+]: 411.1234。Found: 411.1235。
HRMS(ES+) m/z Calcd for C19H19N7O3S + H [(M+H)+]: 426.1343。Found: 426.1344。
4−クロロ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド
HRMS(ES+) m/z Calcd for C27H25ClN6O3S + H [(M+H)+]: 549.1470。Found: 549.1459。
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド トルエン−4−スルホン酸塩
HRMS(ES+) m/z Calcd for C27H25ClN6O3S + H [(M+H)+]: 549.1470。Found: 549.1467。
4−クロロ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド
HRMS(ES+) m/z Calcd for C27H24ClN5O4S + H [(M+H)+]: 550.1311。Found: 550.1311。
4−クロロ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩
HRMS(ES+) m/z Calcd for C26H22ClN5O4S + H [(M+H)+]: 536.1154。Found: 536.1149。
4−アミノ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ−[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩
HRMS(ES+) m/z Calcd for C21H21N5O4S + H [(M+H)+]: 440.1387。Found: 440.1384。
4−クロロ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
4−アミノ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド
HRMS(ES+) m/z Calcd for C29H30N6O4S + H [(M+H)+]: 559.2122。Found: 559.2120。
HRMS(ES+) m/z Calcd for C21H21N5O3S + H [(M+H)+]: 424.1438。Found: 424.1433。
4−アミノ−3−[2−メチル−5−(5−メチル−4H−[1,2,4]トリアゾール−3−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド
HRMS(ES+) m/z Calcd for C21H22N6O3S + H [(M+H)+]: 439.1547。Found: 439.1544。
キナーゼ酵素阻害アッセイ(IC50)
6H−MEKを基質としたc−Raf HTRFアッセイ(用量反応)
本アッセイでは6H−MEKを基質として使用する。c−Rafリン酸化時に、リン酸化された6H−MEKは、ウサギ 抗ホスホ−MEK1/2、Eu標識抗ウサギ、及びAPC標識抗6H抗体によって検出される。
N末端EEタグ化c−RafをHigh-5細胞で発現させた。5Lの培養物をウイルスにより、EE−c−Raf及びFLAG−vSrcについて1:2の比で共トランスフェクトさせ、48時間後に収穫した。細胞ペレットを、5mM EDTA、50mM KF、20mMピロリン酸Na、20mMリン酸β−グリセロール、0.5mM NaVO3、1%NP−40(w/v)及び完全プロテアーゼ錠を含有するTBSで溶解した。溶解物を20,000×gで1時間遠心分離した。上清を8mlの抗タグタンパク質Gセファロースとともに4℃で2時間インキュベートした。その後、樹脂を30倍体積の上記バッファーで洗浄した。c−Rafタンパク質を、100mg/mlのEEペプチドを含有する上述のバッファーとともに、4℃で1時間インキュベートすることにより溶出させた。Amicon Stir CellをYM10膜と用いてタンパク質を濃縮した。濃縮タンパク質を1mM DTT及び 30%グリセロール含有TBSに対して透析した。タンパク質濃度はBioRad DC法で決定した。
6H−MEK1(62−393)の発現用のプラスミドを含有する大腸菌(E. coli)細胞をRich Mediaにおいて、22℃で24時間インキュベートし、1mM IPTGにより誘導した。細胞ペレット50mMを、リン酸カリウムバッファー(pH8.0)、300mM NaCl、5mM MgCl2、10mM CHAPS、2mM TCEP、及び完全プロテアーゼ阻害錠に再懸濁させた。細胞を超音波処理により破壊した。13,000×gで45分の遠心分離により、溶解物を清明化した。上清を50mMリン酸カリウムバッファー(pH8.0)、10mMイミダゾール、4mM TCEP、300mM NaCl、10mM CHAPS、2mM ピロール−2−カルボキシレート、及び100mM ZnCl2で1:1に希釈した後、TALON金属アフィニティー樹脂と4℃で1時間インキュベートした。
本アッセイは6H−MEKを基質として使用する。b−RafWTリン酸化時に、リン酸化6H−MEKは、ウサギ抗ホスホ−MEK1/2、Eu標識抗ウサギ、及びAPC標識抗6H抗体により検出される。
本アッセイは6H−MEKを基質として使用する。b−RafV600Eリン酸化時に、リン酸化6H−MEKは、ウサギ抗ホスホ−MEK1/2、Eu標識抗ウサギ、及びAPC標識抗6H抗体により検出される。
Claims (10)
- 下記式の化合物
R1は、水素、C 1 −C 6 アルキル、C 2 −C 6 アルケニル、C 2 −C 6 アルキニル、C 1 −C 6 アルコキシ、シアノ、NR4R5、トリフルオロメチル及びNO2からなる群より選択され;
R2は例えば、水素、C 1 −C 6 アルキル、置換C 1 −C 6 アルキル、アリール又はヘテロアリール置換C 1 −C 6 アルキル、C 2 −C 6 アルケニル、C 2 −C 6 アルキニル、C 1 −C 6 アルコキシ、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シアノ、ハロゲン、メチルスルホニル、スルホンアミド、トリフルオロメチル、スルホニル尿素、アミド、エステル、カルバメート及び尿素からなる群より選択される1又は2以上の基であり;
R3は、水素、ヒドロキシ、C 1 −C 6 アルキル、置換C 1 −C 6 アルキル、C 1 −C 6 アルコキシ及びNR4R5からなる群より選択され;
環Bは、フェニルであり;
環Aは、更に置換されていてもよい
R4及びR5は、水素、C 1 −C 6 アルキル、又はヒドロキシ若しくはC 1 −C 6 アルコキシで置換されたC 1 −C 6 アルキルから選択され、
XはO又はNHであり、
なお、上記基が置換される場合の置換基は、別途定義された場合を除き、C 1 −C 6 アルキル、C 2 −C 6 アルケニル、C 2 −C 6 アルキニル、ジオキソC 1 −C 6 アルキレン、ハロゲン、ヒドロキシ、CN、CF 3 、NH 2 、N(H、C 1 −C 6 アルキル)、N(C 1 −C 6 アルキル) 2 、アミノカルボニル、カルボキシ、NO 2 、C 1 −C 6 アルコキシ、チオC 1 −C 6 アルコキシ、C 1 −C 6 アルキルスルホニル、アミノスルホニル、C 1 −C 6 アルキルカルボニル、C 1 −C 6 アルキルカルボニルオキシ、C 1 −C 6 アルコキシカルボニル、C 1 −C 6 アルキル−カルボニル−NH、フルオロ−C 1 −C 6 アルキル、フルオロ−C 1 −C 6 アルコキシ、C 1 −C 6 アルコキシ−カルボニル−C 1 −C 6 アルコキシ、カルボキシ−C 1 −C 6 アルコキシ、カルバモイル−C 1 −C 6 アルコキシ、ヒドロキシ−C 1 −C 6 アルコキシ、NH 2 −C 1 −C 6 アルコキシ、N(H、C 1 −C 6 アルキル)−C 1 −C 6 アルコキシ、N(C 1 −C 6 アルキル) 2 −C 1 −C 6 アルコキシ、ベンジルオキシ−C 1 −C 6 アルコキシ、モノ又はジC 1 −C 6 アルキル置換アミノ−スルホニル、並びに、ハロゲン、ヒドロキシ、NH 2 、N(H、C 1 −C 6 アルキル)又はN(C 1 −C 6 アルキル) 2 で置換されていてもよい低級アルキルからなる群より選択される)、
及び、医薬的に許容し得るその塩。 - R1は、水素、C 1 −C 6 アルキル、C 2 −C 6 アルケニル、C 2 −C 6 アルキニル、C 1 −C 6 アルコキシ、シアノ、NR4R5、トリフルオロメチル及びNO2からなる群より選択され;
R2は、水素、C 1 −C 6 アルキル、置換C 1 −C 6 アルキル、アリール又はヘテロアリール置換C 1 −C 6 アルキル、C 2 −C 6 アルケニル、C 2 −C 6 アルキニル、C 1 −C 6 アルコキシ、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シアノ、ハロゲン、メチルスルホニル、スルホンアミド、トリフルオロメチル、スルホニル尿素、アミド、エステル、カルバモイル、カルバメート及び尿素からなる群より選択され;
R3は、水素、C 1 −C 6 アルキル、置換C 1 −C 6 アルキル、C 1 −C 6 アルコキシ及びNR4R5からなる群より選択され;
環Bは、フェニルであり;
環Aは、
R4及びR5は、水素、C 1 −C 6 アルキル、又はヒドロキシ若しくはC 1 −C 6 アルコキシで置換されたC 1 −C 6 アルキルから選択され、
XはO又はNHである、
請求項1記載の式Iの化合物、及び医薬的に許容し得るその塩。 - R1 が、水素又はC 1 −C 6 アルキルであり、環Bの環A結合位に対してパラ位に結合する、請求項1又は請求項2に記載の化合物。
- 環Aは、
(式中、
R2は、水素、C 1 −C 6 アルキル、置換C 1 −C 6 アルキル、アリール又はヘテロアリール置換C 1 −C 6 アルキル、C 2 −C 6 アルケニル、C 2 −C 6 アルキニル、C 1 −C 6 アルコキシ、アリール、置換アリール、ヘテロアリール、置換ヘテロアリール、シアノ、ハロゲン、メチルスルホニル、スルホンアミド、トリフルオロメチル、スルホニル尿素、アミド、エステル、カルバモイル、カルバメート及び尿素からなる群より選択される)、
環Bは、アリール及びヘテロアリールからなる群より選択される、
請求項1〜4のいずれか1項に記載の化合物。 - 4−アミノ−3−[3−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[3−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩、
4−アミノ−3−{5−[4−(2−ヒドロキシ−エチル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩、
4−アミノ−3−[2−メチル−5−(5−メチル−[1,3,4]オキサジアゾール−2−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド トルエン−4−スルホン酸塩、及び
4−アミノ−3−[2−メチル−5−(1−メチル−1H−[1,2,3]トリアゾール−4−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル
からなる群より選択される、請求項1記載の化合物。 - 4−アミノ−3−[2−メチル−5−(1−メチル−1H−[1,2,3]トリアゾール−4−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−アミノ−3−{3−[2−(4−メトキシ−ベンジル)−2H−テトラゾール−5−イル]−フェノキシメチル}−チエノ[3,2−]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{3−[2−(4−メトキシ−ベンジル)−2H−テトラゾール−5−イル]−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−アミノ−3−[3−(2−メチル−2H−テトラゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[3−(2−メチル−2H−テトラゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、及び、
4−アミノ−3−{5−[1−(4−クロロ−ベンジル)−1H−[1,2,3]トリアゾール−4−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド トルエン−4−スルホン酸塩.
からなる群より選択される、請求項1記載の化合物。 - 4−アミノ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[5−(4−クロロ−ベンジル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸、及び、
4−アミノ−3−{5−[5−(4−クロロ−フェニル)−[1,3,4]オキサジアゾール−2−イル]−2−メチル−フェノキシ−メチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩
からなる群より選択される、請求項1記載の化合物。 - 4−アミノ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸、
4−アミノ−3−[2−メチル−5−(3−メチル−[1,2,4]オキサジアゾール−5−イル)−フェノキシメチル]−チエノ−[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミドトリフルオロ酢酸塩、
4−アミノ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、
4−アミノ−3−{5−[4−(4−メトキシ−ベンジル)−5−メチル−4H−[1,2,4]トリアゾール−3−イル]−2−メチル−フェノキシメチル}−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド、
4−アミノ−3−[2−メチル−5−(5−メチル−4H−[1,2,4]トリアゾール−3−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸エチルエステル、及び、
4−アミノ−3−[2−メチル−5−(5−メチル−4H−[1,2,4]トリアゾール−3−イル)−フェノキシメチル]−チエノ[3,2−c]ピリジン−7−カルボン酸(2−ヒドロキシ−エチル)−アミド
からなる群より選択される、請求項1記載の化合物。 - 請求項1〜8のいずれか1項に記載の式Iの化合物、又は医薬的に許容し得るその塩を、医薬的に許容し得る担体と共に含んでなる、医薬組成物。
- 請求項1〜8のいずれか1項に記載の式Iの化合物の使用であって、癌、アテローム性動脈硬化、及び/又は再狭窄の処置に有用な薬剤の調製における使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81761606P | 2006-06-29 | 2006-06-29 | |
US60/817,616 | 2006-06-29 | ||
PCT/EP2007/056241 WO2008000697A1 (en) | 2006-06-29 | 2007-06-22 | Novel 4-amino-3-(-azolyl-phenoxymethyl)-thieno[3,2]pyridine-7-carboxylic acid derivatives |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2009541424A JP2009541424A (ja) | 2009-11-26 |
JP4933617B2 true JP4933617B2 (ja) | 2012-05-16 |
Family
ID=38514272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009517136A Expired - Fee Related JP4933617B2 (ja) | 2006-06-29 | 2007-06-22 | 新規4−アミノ−3−(3−アゾリル−フェノキシメチル)−チエノ[3,2−c]ピリジン−7−カルボン酸誘導体 |
Country Status (16)
Country | Link |
---|---|
US (1) | US7932390B2 (ja) |
EP (1) | EP2038288B1 (ja) |
JP (1) | JP4933617B2 (ja) |
KR (1) | KR101143286B1 (ja) |
CN (1) | CN101479278B (ja) |
AT (1) | ATE489391T1 (ja) |
BR (1) | BRPI0713041A8 (ja) |
CA (1) | CA2655398C (ja) |
DE (1) | DE602007010779D1 (ja) |
DK (1) | DK2038288T3 (ja) |
ES (1) | ES2354637T3 (ja) |
IL (1) | IL195897A (ja) |
MX (1) | MX2008016068A (ja) |
PL (1) | PL2038288T3 (ja) |
PT (1) | PT2038288E (ja) |
WO (1) | WO2008000697A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9540322B2 (en) | 2008-08-18 | 2017-01-10 | Yale University | MIF modulators |
WO2011119894A2 (en) * | 2010-03-24 | 2011-09-29 | Kinagen, Inc | Heterocyclic compounds useful for kinase inhibition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2732970B1 (fr) * | 1995-04-14 | 1997-05-16 | Hoechst Schering Agrevo Sa | Nouveaux derives de l'acide beta-methoxy acrylique, leur procede de preparation et leur application comme pesticides |
UA60365C2 (uk) | 1998-06-04 | 2003-10-15 | Пфайзер Продактс Інк. | Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця |
US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
HN2000000051A (es) | 1999-05-19 | 2001-02-02 | Pfizer Prod Inc | Derivados heterociclicos utiles como agentes anticancerosos |
KR20050116401A (ko) | 2000-11-28 | 2005-12-12 | 화이자 프로덕츠 인크. | 이소티아졸-4-카복사미드의 염 및 과증식-억제제로서의그의 용도 |
SI1499311T1 (sl) | 2002-03-29 | 2010-03-31 | Novartis Vaccines & Diagnostic | Substituirani benzazoli in njihova uporaba kot inhibitorji Raf kinaze |
WO2004041285A1 (en) * | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
EP1620094A4 (en) | 2003-05-06 | 2010-04-28 | Glaxosmithkline Llc | NEW CHEMICAL COMPOUNDS |
US20050020619A1 (en) * | 2003-07-24 | 2005-01-27 | Patrick Betschmann | Thienopyridine kinase inhibitors |
US7202363B2 (en) * | 2003-07-24 | 2007-04-10 | Abbott Laboratories | Thienopyridine and furopyridine kinase inhibitors |
US20050026944A1 (en) * | 2003-07-24 | 2005-02-03 | Patrick Betschmann | Thienopyridine and furopyridine kinase inhibitors |
CN1890249A (zh) | 2003-12-05 | 2007-01-03 | 贝林格尔·英格海姆药物公司 | 作为ikk抑制剂的被取代的3-氨基-噻吩并[2,3-b]吡啶-2-羧酸酰胺化合物 |
US20050256154A1 (en) * | 2004-05-04 | 2005-11-17 | Kin-Chun Luk | 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides |
-
2007
- 2007-06-18 US US11/820,306 patent/US7932390B2/en not_active Expired - Fee Related
- 2007-06-22 KR KR1020087031714A patent/KR101143286B1/ko active IP Right Grant
- 2007-06-22 PT PT07730300T patent/PT2038288E/pt unknown
- 2007-06-22 AT AT07730300T patent/ATE489391T1/de active
- 2007-06-22 DE DE602007010779T patent/DE602007010779D1/de active Active
- 2007-06-22 PL PL07730300T patent/PL2038288T3/pl unknown
- 2007-06-22 MX MX2008016068A patent/MX2008016068A/es active IP Right Grant
- 2007-06-22 BR BRPI0713041A patent/BRPI0713041A8/pt not_active Application Discontinuation
- 2007-06-22 EP EP07730300A patent/EP2038288B1/en active Active
- 2007-06-22 JP JP2009517136A patent/JP4933617B2/ja not_active Expired - Fee Related
- 2007-06-22 DK DK07730300.6T patent/DK2038288T3/da active
- 2007-06-22 ES ES07730300T patent/ES2354637T3/es active Active
- 2007-06-22 CA CA2655398A patent/CA2655398C/en not_active Expired - Fee Related
- 2007-06-22 CN CN2007800239148A patent/CN101479278B/zh not_active Expired - Fee Related
- 2007-06-22 WO PCT/EP2007/056241 patent/WO2008000697A1/en active Application Filing
-
2008
- 2008-12-11 IL IL195897A patent/IL195897A/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP2038288A1 (en) | 2009-03-25 |
MX2008016068A (es) | 2009-01-15 |
DK2038288T3 (da) | 2011-01-03 |
CA2655398A1 (en) | 2008-01-03 |
BRPI0713041A2 (pt) | 2012-04-17 |
US20080009515A1 (en) | 2008-01-10 |
AU2007263770A1 (en) | 2008-01-03 |
WO2008000697A1 (en) | 2008-01-03 |
JP2009541424A (ja) | 2009-11-26 |
PT2038288E (pt) | 2011-01-12 |
US7932390B2 (en) | 2011-04-26 |
ATE489391T1 (de) | 2010-12-15 |
ES2354637T3 (es) | 2011-03-16 |
PL2038288T3 (pl) | 2011-05-31 |
CN101479278A (zh) | 2009-07-08 |
KR101143286B1 (ko) | 2012-05-24 |
KR20090021195A (ko) | 2009-02-27 |
BRPI0713041A8 (pt) | 2019-01-15 |
CA2655398C (en) | 2014-07-29 |
DE602007010779D1 (en) | 2011-01-05 |
EP2038288B1 (en) | 2010-11-24 |
CN101479278B (zh) | 2011-12-07 |
IL195897A (en) | 2016-04-21 |
IL195897A0 (en) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101652654B1 (ko) | 폴리 (adp-리보스) 폴리머라아제-1의 선택적 억제제로서 치환된 프탈라진-1 (2h)-온 유도체 | |
CN110317214B (zh) | 作为蛋白质激酶的调节剂的二芳基巨环 | |
KR101734606B1 (ko) | 질소-함유 헤테로아릴 유도체 | |
KR101483215B1 (ko) | 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체 | |
US20120077828A1 (en) | Chemical compounds | |
US20130018038A1 (en) | Chemical compounds | |
TW200524599A (en) | Substituted tricyclic heterocycles and their uses | |
JP5091237B2 (ja) | チエノ[3,2−c]ピリジン−7−カルボン酸誘導体 | |
JP5296790B2 (ja) | 抗増殖性疾患剤としてのピラゾロ[3,4−d]−ピリミジン誘導体 | |
JP4933617B2 (ja) | 新規4−アミノ−3−(3−アゾリル−フェノキシメチル)−チエノ[3,2−c]ピリジン−7−カルボン酸誘導体 | |
KR20190138661A (ko) | 불소-치환된 인다졸 화합물 및 이의 용도 | |
AU2007263770B2 (en) | Novel 4-amino-3-(-azolyl-phenoxymethyl)-thieno[3,2]pyridine-7-carboxylic acid derivatives | |
WO2022057787A1 (zh) | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110913 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110914 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111213 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120117 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4933617 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150224 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |